TuHURA Biosciences (HURA) Projected to Post Quarterly Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) is anticipated to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.1233) per share for the quarter.

TuHURA Biosciences Stock Down 0.5%

NASDAQ HURA opened at $1.97 on Wednesday. The company has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $1.66. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.44. The firm has a market cap of $119.62 million, a price-to-earnings ratio of -3.94 and a beta of -0.30.

Analysts Set New Price Targets

HURA has been the topic of a number of analyst reports. Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, TuHURA Biosciences currently has an average rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares in the last quarter. Deutsche Bank AG boosted its position in TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after acquiring an additional 54,051 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $97,000. Goldman Sachs Group Inc. purchased a new position in shares of TuHURA Biosciences during the 4th quarter worth approximately $30,000. Finally, Marshall Wace LLP bought a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $79,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.